WallStSmart

Palantir Technologies Inc. (PLTR)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 944% more annual revenue ($46.72B vs $4.48B). PLTR leads profitability with a 36.3% profit margin vs 16.7%. PLTR appears more attractively valued with a PEG of 2.98. PLTR earns a higher WallStSmart Score of 73/100 (B).

PLTR

Strong Buy

73

out of 100

Grade: B

Growth: 8.7Profit: 9.5Value: 2.0Quality: 9.0
Piotroski: 5/9Altman Z: 4.62

SNY

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 6.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PLTRSignificantly Overvalued (-337.0%)

Margin of Safety

-337.0%

Fair Value

$29.48

Current Price

$154.96

$125.48 premium

UndervaluedFair: $29.48Overvalued
SNYSignificantly Overvalued (-89.7%)

Margin of Safety

-89.7%

Fair Value

$24.79

Current Price

$46.03

$21.24 premium

UndervaluedFair: $24.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PLTR6 strengths · Avg: 10.0/10
Market CapQuality
$370.18B10/10

Mega-cap, among the largest globally

Profit MarginProfitability
36.3%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
40.9%10/10

Strong operational efficiency at 40.9%

Revenue GrowthGrowth
70.0%10/10

Revenue surging 70.0% year-over-year

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.6210/10

Safe zone — low bankruptcy risk

SNY3 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Market CapQuality
$109.03B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.59B8/10

Generating 1.6B in free cash flow

Areas to Watch

PLTR3 concerns · Avg: 2.0/10
PEG RatioValuation
2.982/10

Expensive relative to growth rate

P/E RatioValuation
245.7x2/10

Premium valuation, high expectations priced in

Price/BookValuation
50.1x2/10

Trading at 50.1x book value

SNY3 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Return on EquityProfitability
6.7%3/10

ROE of 6.7% — below average capital efficiency

PEG RatioValuation
4.322/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : PLTR

The strongest argument for PLTR centers on Market Cap, Profit Margin, Operating Margin. Profitability is solid with margins at 36.3% and operating margin at 40.9%. Revenue growth of 70.0% demonstrates continued momentum.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.

Bear Case : PLTR

The primary concerns for PLTR are PEG Ratio, P/E Ratio, Price/Book. A P/E of 245.7x leaves little room for execution misses.

Bear Case : SNY

The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.

Key Dynamics to Monitor

PLTR profiles as a growth stock while SNY is a mature play — different risk/reward profiles.

PLTR carries more volatility with a beta of 1.74 — expect wider price swings.

PLTR is growing revenue faster at 70.0% — sustainability is the question.

SNY generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

PLTR scores higher overall (73/100 vs 49/100), backed by strong 36.3% margins and 70.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Palantir Technologies Inc.

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Palantir Technologies Inc. creates and implements software platforms for the intelligence community in the United States to assist in counterterrorism investigations and operations. The company is headquartered in Denver, Colorado.

Visit Website →

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?